Genetic Modifiers of Hemoglobin Expression from a Clinical Perspective in Hemoglobinopathy Patients with Beta Thalassemia and Sickle Cell Disease
International Journal of Molecular Sciences · 05.11.2024 · 25 (22) · 11886
DOI: 10.3390/ijms252211886 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 05.11.2024. Verfasst von Michael D Diamantidis und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Thalassemia and Sickle Cell Disease Unit, General Hospital of Larissa, 41221 Larissa, Greece. Hauptthemen laut MEDLINE: beta-Thalassemia, Anemia, Sickle Cell, Genetic Therapy, Hemoglobins. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 187 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hemoglobinopathies, namely β-thalassemia and sickle cell disease (SCD), are hereditary diseases, characterized by molecular genetic aberrations in the beta chains of hemoglobin. These defects affect the normal production of hemoglobin with severe anemia due to less or no amount of beta globins in patients with β-thalassemia (quantitative disorder), while SCD is a serious disease in which a mutated form of hemoglobin distorts the red blood cells into a crescent shape at low oxygen levels (qualitative disorder). Despite the revolutionary progress in recent years with the approval of gene therapy and gene editing for specific patients, there is an unmet need for highlighting the mechanisms influencing hemoglobin production and for the development of novel drugs and targeted therapies. The identification of the transcription factors and other genetic modifiers of hemoglobin expression is of utmost importance for discovering novel therapeutic approaches for patients with hemoglobinopathies. The aim of this review is to describe these complex molecular mechanisms and pathways affecting hemoglobin expression and to highlight the relevant investigational approaches or pharmaceutical interventions focusing on restoring the hemoglobin normal function by linking the molecular background of the disease with the clinical perspective. All the associated drugs increasing the hemoglobin expression in patients with hemoglobinopathies, along with gene therapy and gene editing, are also discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Thalassemia and Sickle Cell Disease Unit, General Hospital of Larissa, 41221 Larissa, Greece.
- Thalassemia and Sickle Cell Disease Prevention Unit, General Hospital of Larissa, 41221 Larissa, Greece.
- Thalassemia and Sickle Cell Disease Unit, AHEPA University General Hospital, 41221 Thessaloniki, Greece.
- Center of Expertise in Hemoglobinopathies and Their Complications, Thalassemia and Sickle Cell Disease Unit, Hippokration General Hospital, 41221 Athens, Greece.
ORCID-Profile: Michael D Diamantidis, Sophia Delicou
Zitieren
APA
Diamantidis, M. D., Ikonomou, G., Argyrakouli, I., Pantelidou, D., Delicou, S., & International Hemoglobinopathy Research Network (INHERENT) (2024). Genetic Modifiers of Hemoglobin Expression from a Clinical Perspective in Hemoglobinopathy Patients with Beta Thalassemia and Sickle Cell Disease. International Journal of Molecular Sciences, 25(22), 11886. https://doi.org/10.3390/ijms252211886
Vancouver
Diamantidis MD, Ikonomou G, Argyrakouli I, Pantelidou D, Delicou S, International Hemoglobinopathy Research Network (INHERENT). Genetic Modifiers of Hemoglobin Expression from a Clinical Perspective in Hemoglobinopathy Patients with Beta Thalassemia and Sickle Cell Disease. International Journal of Molecular Sciences. 2024;25(22):11886. doi:10.3390/ijms252211886
BibTeX
@article{Diamantidis2024,
author = {Diamantidis, Michael D and Ikonomou, Georgia and Argyrakouli, Ioanna and Pantelidou, Despoina and Delicou, Sophia and International Hemoglobinopathy Research Network (INHERENT), International Hemoglobinopathy Research Network (INHERENT)},
title = {Genetic Modifiers of Hemoglobin Expression from a Clinical Perspective in Hemoglobinopathy Patients with Beta Thalassemia and Sickle Cell Disease},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {22},
pages = {11886},
doi = {10.3390/ijms252211886}
}
EUVIMED